2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2208 Delayed skeletal-related events in newly diagnosed multiple myeloma: Real-world characterization and risk factors in the contemporary treatment era

Asha Ravichandran, MD, Simon Zhen, M.D2, Divaya Bhutani, MD3, Suzanne Lentzsch, MD, PhD4, Rajshekhar Chakraborty, MD5, Michael Sang Hughes, MD6
1 Columbia University Irving Medical Center/Herbert Irving Pavilion, New York, New York, United States
2 Columbia University Irving Medical Center/Herbert Irving Pavilion, New York, New York, United States
3 Columbia University Irving Medical Center/Herbert Irving Pavilion, New York, New York, United States
4 Columbia University Irving Medical Center/Herbert Irving Pavilion, New York, New York, United States
5 Columbia University Irving Medical Center/Herbert Irving Pavilion, New York, New York, United States
6 Columbia University Irving Medical Center/Herbert Irving Pavilion, New York, New York, United States

BACKGROUND

Up to 40% of initial skeletal-related events (SREs) occur beyond 90 days after starting therapy, leading to substantial morbidity [Raje 2018]. Such “delayed” SREs are not well-characterized in the modern era. In a real-world cohort of newly diagnosed multiple myeloma (NDMM) patients, we described delayed SREs and investigated possible predictors.

METHODS

We extracted longitudinal data from the medical records of 388 patients with NDMM treated between 5/2016-6/2026. An SRE was defined as a lesion causing a pathologic fracture, compressing the spinal cord, requiring procedural intervention, or requiring palliative radiotherapy [Raje 2018]. Delayed SRE was defined as a first SRE occurring >90 days (“d+90”) after treatment initiation. Baseline comparisons used Fisher exact and Wilcoxon tests. Associations with delayed SRE were evaluated with landmarked Cox modeling of patients alive and SRE-free at d+90. Pre-SRE death was treated as a competing event. P values were not adjusted given the study’s exploratory nature.

RESULTS

Median patient age was 69.3 years; the population was 52.3% male (M:F 203:185). Reflecting our center’s catchment area, 41.2% (160/388) were of self-reported Hispanic ethnicity. High-risk NDMM criteria by Consensus Genomic Staging were met in 19.3% (75/388). Evidence of bone disease at diagnosis was present in 78.4% (302/385): 9.0% (35/388) and 33.2% (129/388) underwent whole-body MRI or PET-CT, respectively. Frontline anti-CD38+ agents were administered in 64.1%, and 39.2% of patients received autologous stem cell transplant. IMWG response ≥VGPR by 6 months was achieved in 70.6% (197/279 evaluable). Median follow-up time was 48.2 months.

An SRE occurred in 65.2% (253/388) of all cohort patients. Fractures were present in the majority (88.9%, 225/253). Operative procedure was performed in 26.9% (68/253), and palliative radiation in 20.6% (52/253). Cord compression occurred in 15.4% (39/253). Bone-modifying agents (BMAs) were administered at least once to 73.5% (285/388) at or after diagnosis, with 1 patient prescribed prior BMA. There was 1 case of osteonecrosis of the jaw. Baseline categorical comparisons in patients with vs without any SRE confirmed higher rates of hypercalcemia (p=0.024) and bony disease (p<0.001). Patients with any SRE also exhibited higher rates of abnormal LDH (31.8% vs 19.8%, p=0.031) and del1p (14.6% vs 4.1%, p=0.007). First SRE occurred pre-induction and within 30 days of treatment initiation in 60.1% (152/253) and 70.4% (178/253) of instances, respectively; in 5.9% (15/253), exact timing could not be confirmed. From d+31-90, 4.0% (10/253) SREs occurred. Among patients with exact BMA timing available, administration rate by d+90 was 49.7% (150/302).

Of all 178 patients alive and SRE-free by d+90, delayed SREs occurred in 28.1% (50/178). In 36.0% (18/50) patients with delayed SRE, disease progression had previously occurred or SRE was the defining event. BMAs had been previously administered to 28/50 (56.0%). By univariate Cox, increased baseline M-protein (HR 1.20 per 1g/dL increase, p<0.001) and extraosseous extramedullary disease (EMD; HR 2.22, p=0.025) were associated with delayed SRE. Bone disease at diagnosis trended toward association (HR 1.81, p=0.067). BMA exposure by d+90 (p=0.176) and sex (p=0.140) were not associated. In multivariable Cox modeling (n=118 complete cases, 40 events) of baseline M-protein, extraosseous EMD, baseline bone disease, and BMA receipt by d+90, increased baseline M-protein was associated with delayed SRE (HR 1.22 per 1g/dL increase, p=0.001). Extraosseous EMD trended toward association (HR 2.09, p=0.070). Bone disease at diagnosis was not associated (p=0.564). BMA receipt by d+90 was paradoxically associated with increased risk (HR 1.99, p=0.047). When adjusted for bone marrow plasma cell percentage instead of bone disease, baseline M-protein remained associated (HR 1.16 per 1g/dL increase, p=0.029); BMA administration by d+90 was not (p=0.230).

CONCLUSION

In a real-world NDMM cohort, 64% of delayed SREs occurred without prior or concurrent disease progression. Higher baseline M-protein was independently associated with delayed SREs. Association of delayed SRE with BMA receipt by that timepoint was sensitive to cohort and covariate specification, likely reflecting confounding. In the era of highly effective frontline NDMM treatment, further study of risk-adapted strategies for skeletal surveillance and BMA administration is warranted.
Asha Ravichandran, MD: No relevant conflicts of interest to declare.